請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34412
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳秀熙(Tony Hsiu-Hsi Chen) | |
dc.contributor.author | Yi-Chia Lee | en |
dc.contributor.author | 李宜家 | zh_TW |
dc.date.accessioned | 2021-06-13T06:07:17Z | - |
dc.date.available | 2008-08-03 | |
dc.date.copyright | 2006-08-03 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-06-12 | |
dc.identifier.citation | Chapter 1.
1.Chen H, Ward M H, Graubard B I, Heineman E F, Markin R M, Potischman N A, Russell R M, Weisenburger D D, Tucker Katherine. Dietary patterns and adenocarcinoma of the esophagus and distal stomach. Am J Clin Nutr 2002; 75: 137-144. 2.Correa P: Diet modification and gastric cancer prevention. J Natl Cancer Inst 1992;12: 75-8. 3.Forman D, Newell DG, Fullreton F, Yarnell JWG, Stacey AR, Wald N, Sitas F. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991;302: 1302-5. 4.Ito LS, Inoue M, Tajima K, Yamamura Y, Kodera Y, Hirose K, Takezaki T, Hamajima N, Kuroishi T, Tominaga S. Dietary factors and the risk of gastric cancer among Japanese women: a comparison between the differentiated and non-differentiated subtypes. Annals of Epidemiology 2003;13:24-31. 5.Wu MS, Chen CJ, Lin JT. Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1878-1882. 6.Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 1995; 333: 32-41. 7.Marjorie L. M., Andrea S. R., Eric J. J., Ann. C., Eugenia E. C., Michael J. T. A prospective study of diet and stomach cancer mortality in United States men and women. Cancer Epidemiol Biomarkers Prev. 2001;10: 1201-5. 8.Department of Health. Main causes of death by cancer in Taiwan. Taipei (Taiwan): Department of Health, Executive Yuan; 2004. 9.91年度連江縣衛生局委託計畫: 馬祖社區整合性道點篩檢計畫計畫成果報告書. 陳秀熙教授等人. 10.95年至97年馬祖及其台灣移民之胃癌預防性介入計畫書. 台灣篩檢學會. 陳秀熙教授, 林肇堂教授等人. 11.Uemura N, Okamoto S, Yamamoto S, Matsunura N, Yamaguchi N, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylory infection and the development of gastric cancer. N Engl J Med 2002;345:784-9. 12.Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311-5. 13.Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res.1992;52:6735-6740. Chapter 2. 1.Department of Health. Main causes of death by cancer in Taiwan. Taipei (Taiwan): Department of Health, Executive Yuan; 2004. 2.Tsubono Y, Hisamichi S. Screening for gastric cancer in Japan. Gastric Cancer. 2000;3:9-18. 3.Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114:1169-79. 4.Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999;94:2373-9. 5.Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H. pylori infection with gastric carcinoma: a Meta analysis. World J Gastroenterol. 2001;7:801-4. 6.Gail MH, You WC, Chang YS, Zhang L, Blot WJ, Brown LM, Groves FD, Heinrich JP, Hu J, Jin ML, Li JY, Liu WD, Ma JL, Mark SD, Rabkin CS, Fraumeni JF Jr, Xu GW. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Control Clin Trials 1998;19:352-369. 7.Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-1888. 8.Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT, Yeung CK, Chao W, Chung SC. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7-14. 9.Moayyedi P, Feltbower R, Crocombe W, Mason S, Atha P, Brown J, Dowell AC, Richards ID, Axon AT. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. Aliment Pharmacol Ther 2000;14:719-728. 10.Mason J, Axon AT, Forman D, Duffett S, Drummond M, Crocombe W, Feltbower R, Mason S, Brown J, Moayyedi P; Leeds HELP Study Group. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther. 2002 ;16:559-68. 11.Guo HQ, Guan P, Shi HL, Zhang X, Zhou BS, Yuan Y. Prospective cohort study of comprehensive prevention to gastric cancer. World J Gastroenterol. 2003;9:432-6. 12.Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54:1536-40. 13.Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT, Yeung CK, Chao W, Chung SC. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000;119:7-14. 14.Lee YC, Wu HM, Chen TH, Liu TY, Chiu HM, Chang CC, Wang HP, Wu MS, Chiang H, Wu MC, Lin JT. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and retreat initial treatment failures. Helicobacter (revised). 15.Witteman EM, Mravunac M, Becx MJ, Hopman WP, Verschoor JS, Tytgat GN, de Koning RW. Improvement of gastric inflammation and resolution of epithelial damage one year after eradication of Helicobacter pylori. J Clin Pathol. 1995;48:250-6. 16.Forbes GM, Warren JR, Glaser ME, Cullen DJ, Marshall BJ, Collins BJ. Long-term follow-up of gastric histology after Helicobacter pylori eradication. J Gastroenterol Hepatol. 1996;11:670-3. 17.van der Hulst RW, van der Ende A, Dekker FW, Ten Kate FJ, Weel JF, Keller JJ, Kruizinga SP, Dankert J, Tytgat GN. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology. 1997;113:25-30. 18.Ciok J, Dzieniszewski J, Lucer C. Helicobacter pylori eradication and antral intestinal metaplasia--two years follow-up study. J Physiol Pharmacol. 1997;48 Suppl 4:115-22. 19.Maconi G, Lazzaroni M, Sangaletti O, Bargiggia S, Vago L, Porro GB. Effect of Helicobacter pylori eradication on gastric histology, serum gastrin and pepsinogen I levels, and gastric emptying in patients with gastric ulcer. Am J Gastroenterol. 1997;92:1844-8. 20.Tucci A, Poli L, Tosetti C, Biasco G, Grigioni W, Varoli O, Mazzoni C, Paparo GF, Stanghellini V, Caletti G. Reversal of fundic atrophy after eradication of Helicobacter pylori. Am J Gastroenterol. 1998;93:1425-31. 21.Oberhuber G, Wuendisch T, Rappel S, Stolte M. Significant improvement of atrophy after eradication therapy in atrophic body gastritis. Pathol Res Pract. 1998;194:609-13. 22.Tepes B, Kavcic B, Gubina M, Krizman I. A four-year follow-up of duodenal ulcer patients after Helicobacter pylori eradication. Hepatogastroenterology. 1999;46:1746-50. 23.Kyzekova J, Mour J. The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. Hepatogastroenterology. 1999;46:2048-56. 24.Annibale B, Aprile MR, D'ambra G, Caruana P, Bordi C, Delle Fave G. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther. 2000;14:625-34. 25.Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT, Yeung CK, Chao W, Chung SC. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000;119:7-14. 26.Kim N, Lim SH, Lee KH, Choi SE, Jung HC, Song IS, Kim CY. Long-term effects of Helicobacter pylori eradication on intestinal metaplasia in patients with duodenal and benign gastric ulcers. Dig Dis Sci. 2000;45:1754-62. 27.Hsu PI, Lai KH, Tseng HH, Lin CK, Lo GH, Cheng JS, Chan HH, Hsu JH, Jou HS, Ger LP, Chen W, Hsu PN. Impact of Helicobacter pylori eradication on the development of MALT, gland atrophy and intestinal metaplasia of the antrum. Zhonghua Yi Xue Za Zhi (Taipei). 2000;63:279-87. 28.Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, Yokoyama T, Watanabe M. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med. 2001;134:380-6. 29.Salih BA, Abasiyanik MF, Saribasak H, Huten O, Sander E. A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology. Dig Dis Sci. 2005;50:1517-22. 30.Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54:1536-40. 31.Lahner E, Bordi C, Cattaruzza MS, Iannoni C, Milione M, Delle Fave G, Annibale B. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005;22:471-81. 32.Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet. 1996;348:150-4. 33.Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med. 1999;159:142-8. 34.McCulloch P, Niita ME, Kazi H, Gama-Rodrigues JJ. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg. 2005;92:5-13. 35.Etoh T, Katai H, Fukagawa T, Sano T, Oda I, Gotoda T, Yoshimura K, Sasako M. Treatment of early gastric cancer in the elderly patient: results of EMR and gastrectomy at a national referral center in Japan. Gastrointest Endosc. 2005;62:868-71. 36.Miki K, Ichinose M, Ishikawa KB, Yahagi N, Matsushima M, Kakei N, Tsukada S, Kido M, Ishihama S, Shimizu Y, et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res. 1993;84:1086-90. 37.Miki K. Gastric cancer screening using serum tests (stomach dry dock). Study of the systems of the first screening for cancer-susceptible subjects by serum pepsinogen levels and the secondary close-examination by every-other-year panendoscopy (in Japanese). J Gastroenterol Mass Survey 1994;32:19-30 38.Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens. Jpn J Cancer Res. 1995;86:1210-5. 39.Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut. 1999;44:693-7. 40.Yamaji Y, Mitsushima T, Ikuma H, Okamoto M, Yoshida H, Kawabe T, Shiratori Y, Saito K, Yokouchi K, Omata M. Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects. Gut. 2001;49:335-40. 41.Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol. 2003;98:735-9. 42.Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen. 2004;11:141-7. Chapter 3. 1.Department of Health. Main causes of death by cancer in Taiwan. Taipei (Taiwan): Department of Health, Executive Yuan; 2004. 2.Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-6740. 3.Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-1179. 4.Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999;94:2373-2379. 5.Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194. 6.Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-180. 7.Ducons JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollon F. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999;13:775-780. 8.Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:647-654. 9.Poon SK, Chang CS, Su J, Lai CH, Yang CC, Chen GH, Wang WC. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment Pharmacol Ther 2002;16:291-296. 10.Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol. 2001;36:690-700. 11.Langtry HD, Lamb HM. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs. 1998;56:487-515. 12.Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, Santarelli L, Arancio F, Gasbarrini G. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339-1343. 13.Bilardi C, Dulbecco P, Zentilin P, Reglioni S, Iiritano E, Parodi A, Accornero L, Savarino E, Mansi C, Mamone M, Vigneri S, Savarino V. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004;2:997-1002. 14.Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caro S, Gabrielli M, Santarelli L, Zocco MA, Ojetti V, Carloni E, Cammarota G, Gasbarrini G, Gasbarrini A. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18:627-633. 15.Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488-496. 16.Chen TH, Chiu YH, Luh DL, Yen MF, Wu HM, Chen LS, Tung TH, Huang CC, Chan CC, Shiu MN, Yeh YP, Liou HH, Liao CS, Lai HC, Chiang CP, Peng HL, Tseng CD, Yen MS, Hsu WC, Chen CH; Taiwan Community-Based Integrated Screening Group. Community-based multiple screening model: design, implementation, and analysis of 42,387 participants. Cancer 2004;100:1734-1743. 17.Chen TS, Chang FY, Chen PC, Huang TW, Ou JT, Tsai MH, Wu MS, Lin JT. Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol 2003;18:1237-1243. 18.Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12. 19.Gail MH, You WC, Chang YS, Zhang L, Blot WJ, Brown LM, Groves FD, Heinrich JP, Hu J, Jin ML, Li JY, Liu WD, Ma JL, Mark SD, Rabkin CS, Fraumeni JF Jr, Xu GW. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Control Clin Trials 1998;19:352-369. 20.Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT, Yeung CK, Chao W, Chung SC. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7-14. 21.Moayyedi P, Feltbower R, Crocombe W, Mason S, Atha P, Brown J, Dowell AC, Richards ID, Axon AT. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. Aliment Pharmacol Ther 2000;14:719-728. 22.Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Ruffalo SM, Laine L Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med. 2000;160:1285-1291. 23.Qasim A, O'Morain CA. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 2002;16 Suppl 1:24-30. 24.Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-1343. 25.Gisbert JP, Pajares JM. Helicobacter pylori 'rescue' therapy after failure of two eradication treatments. Helicobacter 2005;10:363-72. 26.Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, Wu JJ. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther 2003;18:347-353. 27.Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005;21:91-96. 28.Huang AH, Sheu BS, Yang HB, Huang CC, Wu JJ, Lin XZ. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc 2000;99:704-709. 29.Wong WM, Gu Q, Lam SK, Fung FM, Lai KC, Hu WH, Yee YK, Chan CK, Xia HH, Yuen MF, Wong BC. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:553-560. 30.Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, Bergoli ML, Andriulli A. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 2001;96:58-62. 31.Wong WM, Wong BC, Lu H, Gu Q, Yin Y, Wang WH, Fung FM, Lai KC, Xia HH, Xiao SD, Lam SK. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther. 2002;16:793-798. 32.Bosques-Padilla FJ, Garza-Gonzalez E, Calderon-Lozano IE, Reed-SanRoman G, de Arino Suarez M, Valdovinos-Diaz MA, Orozco-Gamiz A, Blancas-Valencia JM, Tamayo-de la Cuesta JL. Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment. Helicobacter 2004;9:417-421. 33.De Francesco V, Della Valle N, Stoppino V, Amoruso A, Muscatiello N, Panella C, Ierardi E. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2004;19:993-998. 34.Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut. 2005;54:735-8. Chapter 4. 1.Department of Health. Main causes of death by cancer in Taiwan. Taipei (Taiwan): Department of Health, Executive Yuan; 2004. 2.Tsubono Y, Hisamichi S. Screening for gastric cancer in Japan. Gastric Cancer. 2000;3:9-18. 3.Miki K, Ichinose M, Ishikawa KB, Yahagi N, Matsushima M, Kakei N, Tsukada S, Kido M, Ishihama S, Shimizu Y, et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res. 1993;84:1086-90. 4.Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut. 1999;44:693-7. 5.Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol. 2003;98:735-9. 6.Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T, Omata M. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54:764-8. 7.Broutet N, Plebani M, Sakarovitch C, Sipponen P, Megraud F; Eurohepygast Study Group. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer. 2003;88:1239-47. 8.Etoh T, Katai H, Fukagawa T, Sano T, Oda I, Gotoda T, Yoshimura K, Sasako M. Treatment of early gastric cancer in the elderly patient: results of EMR and gastrectomy at a national referral center in Japan. Gastrointest Endosc. 2005;62:868-71. 9.Bando E, Kojima N, Kawamura T, Takahashi S, Fukushima N, Yonemura Y. Prognostic value of age and sex in early gastric cancer. Br J Surg. 2004;91:1197-1201. 10.McCulloch P, Niita ME, Kazi H, Gama-Rodrigues JJ. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg. 2005;92:5-13. 11.Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet. 1996;348:150-4. 12.Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med. 1999;159:142-8. 13.Mason J, Axon AT, Forman D, Duffett S, Drummond M, Crocombe W, Feltbower R, Mason S, Brown J, Moayyedi P; Leeds HELP Study Group. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther. 2002;16:559-68. 14.Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127-1131. 15.Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784-789. 16.Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114:1169-1179. 17.Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999;94:2373-2379. 18.Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187-194. 19.Liu TY, Lin JT, Chen TH. Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer. J Med Screen. 2006. (accepted) 20.Lee YC, Wu HM, Chen TH, Liu TY, Chiu HM, Chang CC, Wang HP, Wu MS, Chiang H, Wu MC, Lin JT. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and retreat initial treatment failures. Helicobacter. 2006. 21.Chen SY, Liu TY, Shun CT, Wu MS, Lu TH, Lin JT, Sheu JC, Santella RM, Chen CJ. Modification effects of GSTM1, GSTT1 and CYP2E1 polymorphisms on associations between raw salted food and incomplete intestinal metaplasia in a high-risk area of stomach cancer. Int J Cancer. 2004;108:606-612. 22.Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res.1992;52:6735-6740. 23.Chen TH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics. 2000;56:167-72. 24.Shiu MN, Chen TH. Impact of betel quid, tobacco and alcohol on three-stage disease natural history of oral leukoplakia and cancer: implication for prevention of oral cancer. Eur J Cancer Prev. 2004;13:39-45. 25.Wu HM, Yen MF, Chen THH. SAS macro program for non-homogeneous Markov process in modeling multi-state disease progression. Computer Methods and Programs in Biomedicine. 2004;75:95-105. 26.Wu TC, Chen LK, Hwang SJ. Seroprevalence of Helicobacter pylori in school-aged Chinese in Taipei City and relationship between ABO blood groups. World J Gastroenterol. 2003;9:1752-5. 27.Rowland M, Daly L, Vaughan M, Higgins A, Bourke B, Drumm B. Age-specific incidence of Helicobacter pylori. Gastroenterology. 2006;130:65-72. 28.Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol. 2005;100:2083-99. 29.Chen TS, Chang FY, Chen PC, Huang TW, Ou JT, Tsai MH, Wu MS, Lin JT. Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol. 2003;18:1237-1243. 30.Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-180 31.Voutilainen ME, Juhola MT. Evaluation of the diagnostic accuracy of gastroscopy to detect gastric tumours: clinicopathological features and prognosis of patients with gastric cancer missed on endoscopy. Eur J Gastroenterol Hepatol. 2005;17:1345-9. 32.Waring JP, Baron TH, Hirota WK, Goldstein JL, Jacobson BC, Leighton JA, Mallery JS, Faigel DO; American Society for Gastrointestinal Endoscopy, Standards of Practice Committee. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. Gastrointest Endosc. 2003;58:317-22. 33.Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22:290-308. 34.Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855-9. 35.Tucci A, Poli L, Tosetti C, Biasco G, Grigioni W, Varoli O, Mazzoni C, Paparo GF, Stanghellini V, Caletti G. Reversal of fundic atrophy after eradication of Helicobacter pylori. Am J Gastroenterol. 1998;93:1425-31. 36.Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT, Yeung CK, Chao W, Chung SC. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000;119:7-14. 37.Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54:1536-40. 38.Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311-5. 39.Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, Guilherme M, Barbosa J, Lomba-Viana H, Silva R, Moreira-Dias L. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol. 2004;57:177-82. 40.Feldman H, Friedman LS, Sleisenger MH. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 7th ed. Philadelphia, Md: Saunders; 2003. 41.Wu MS, Chen CJ, Lin JT. Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1878-1882. 42.Kikuchi S, Dore MP. Epidemiology of Helicobacter pylori Infection. Helicobacter. 2005;10 Suppl 1:1-4. 43.Ohata H, Oka M, Yanaoka K, Shimizu Y, Mukoubayashi C, Mugitani K, Iwane M, Nakamura H, Tamai H, Arii K, Nakata H, Yoshimura N, Takeshita T, Miki K, Mohara O, Ichinose M. Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography. Cancer Sci. 2005;96:713-20. 44.Sugano K, Sato K, Yao K. New diagnostic approaches for early detection of gastric cancer. Dig Dis. 2004;22:327-33. 45.Sharma P, Vakil N. Review article: Helicobacter pylori and reflux disease. Aliment Pharmacol Ther. 2003;17:297-305. 46.Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut. 2005;54:735-8. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34412 | - |
dc.description.abstract | 第一部份
雖然幽門螺旋桿菌的除菌治療可以減少胃癌的發生,然而針對整個社區的一般民眾而言,幽門螺旋桿菌除菌治療之最佳處方目前並不了解,因此,本論文的第一部分,報告一種新型的幽門螺旋桿菌除菌治療流程之效果,此計畫乃基於檢驗、除菌、再檢驗、再除菌(test-treat-retest-retreat initial failures) 的流程。 於2004至2005年,在馬祖地區,我們總共收集2,658位居民接受碳13幽門螺旋桿菌吹氣試驗 (13C urea breath test),以確定個案與否感染幽門螺旋桿菌,而幽門螺旋桿菌陽性的個案,將接受7天的標準三合一治療,此第一線治療包含: 每天40 mg 之耐適恩 (esomeprazole),以及早晚各1 g之安莫西林 (amoxicillin),再加上早晚各500 mg 之開羅里黴素 (clarithromycin),若是個案第一線治療失敗,會追加10天的再治療,此再治療的處方包含: 每天40 mg的耐適恩 (esomeprazole),早晚各1 g的安莫西林 (amoxicillin),以及每天500 mg的可樂必妥 (levofloxacin),而處方的除菌效果及負作用,我們各於治療後六週整體評估。 基於886位清楚回答之個案,分析結果顯示幽門螺旋桿菌除菌的效果如下: 第一線治療有效之除菌率為86.9% (95% 信賴區間: 84.7% ~ 89.1%),若針對完全遵守治療流程、完整服用藥物之個案來說,有效之除菌率為88.7% (95% 信賴區間: 86.5% ~ 90.9%),而就再治療之處方而言,它可以成功治癒91.4% 之第一線藥物除菌失敗者 (總共有105位個案,95% 信賴區間: 86% ~ 96.8%),有798位個案達到藥物的完整順從率 (90.1%),而在105位接受再治療的個案,其藥物之完整服用順從率為100%。就藥物負作用來說,有24% 的個案發生了輕微的負作用,但是只有極少數因而中斷治療。就接受本計畫兩階段除菌處方 (幽門螺旋桿菌除菌治療以及再治療) 之個案,其成功除菌治療比率高達97.7% (95% 信賴區間: 96.7% ~ 98.7%),而若是針對完全順從處方服藥之個案,成功除菌率為98.8% (95% 信賴區間: 98.5% ~ 99.3%),而影響除菌治療成功與否之最關鍵因子為病患的藥物順應性,若順應性差,其治療失敗之風險比為 3.3 (95% 信賴區間: 1.99 ~ 5.48)。 第一階段總結來說,我們發現以開羅里黴素 (clarithromycin) 為基礎的初段治療,以及可樂必妥 (levofloxacin) 為基礎的再治療,對無症狀之一般族群來說,是一個非常有效的除菌處方,這樣的兩階段除菌治療方針基本上相當安全,病患的順應度亦高,可以有效地清除幽門螺旋桿菌。 第二部份 因為胃癌的初段預方及次段預防之防治方針,都可以有效降低胃癌的死亡率,然而,我們對於其相對之成本效果,目前並沒有結論,因此,論文之第二部分主要探討胃癌初段預防及次段預防的相對成本效果,我們將論文第一部分所執行之研究,與先前1995至1999年之胃癌次段篩檢計畫來做比較。此外,我們也探討胃癌篩檢之最佳起始年齡,以及胃癌篩檢之最佳篩檢間隔。 針對胃癌風險特高之馬祖居民,第一次之胃癌預防介入,為1995至1999年所執行之胃癌次段預防,此次段預防乃以胃蛋白脢原 (pepsinogen) 之血清學測量做為第一階段篩檢之工具,而證實為高風險之民眾將接受第二階段內視鏡之確診。而第二次之胃癌預防介入,乃介於2004及2005年之初段預防 (即本論文的第一部分),此計畫使用幽門螺旋桿菌之除菌治療,作為胃癌初段預防之工具。 我們根據哥利亞 (Correa) 的胃癌發展模式,以電腦模擬胃癌之自然病史,並使用單方向之敏感度分析 (one-way sensitivity analysis),及隨機性之敏感度分析 (probabilistic sensitivity analysis),針對不確定之參數進行不同範圍之檢視。主要之測量指標為多增加一單位之平均餘命所需要之額外花費。我們使用每年3% 的折扣率 (discounted rate) 針對成本與效果做折價。初段預防及次段預防間之相對成本及效果比較,我們使用增量成本效果比(incremental cost-effective ratio: ICER) 來做分析。 研究結果發現,依據我們建構的胃癌自然病史推演,與實際之統計資料相較,並無顯著之差異。若將胃癌初段預防 (於30歲時執行一次幽門螺旋桿菌治療) 與完全沒有篩檢介入相較,每增加一單位之平均餘命將花費美金 $17,044元。而胃癌初段預防,基本上從愈年輕之時候開始篩檢,其成效愈佳,相對地,若由較晚之年紀開始篩檢,或者以週期性篩檢之方式執行,其增量成本效果比將大為上升。若將胃癌之次段預防 (於50歲開始每年執行篩檢) 與完全沒有篩檢相較,每增加加一單位之平均餘命需花費美金 $29,741元,而次段預防在不同之起始年齡或不同之篩檢間隔時間,其增量成本效果比 (ICER) 卻無顯著的差別。 若我們直接比較初段預防及次段預防,不論願意付出之最高金額 (ceiling ratio) 為美金 $15,762元 (台灣合理標準),或是美金 $50,000元 (美國合理標準),胃癌之初段預防都比次段預防較符合成本效果,其相對之增量成本效果比 (ICER)主要由兩個因素決定其優勢性: 第一個因素: 幽門螺旋桿菌的感染率,第二個因素: 胃癌次段預防中早期胃癌所佔之比例。 本研究顯示,胃癌之初段預防,並且是於群眾年輕時給予一次之幽門螺旋桿菌除菌治療,為一最佳之防治方案。然而,胃癌初段預防及次段預防之間的選擇,仍可能受到幽門螺旋桿菌的感染風險,以及早期胃癌偵測率之不同所影響,因而結果可能因地而異。 | zh_TW |
dc.description.abstract | Part I
Although eradication of Helicobacter pylori (H. pylori) infection can decrease the risk of gastric cancer, the optimal regimen for treating the general population remains unclear. In the first part of thesis, we reported the eradication rate (intention-to-treat and per protocol) of a community-based H. pylori therapy using the strategy of test, treat, retest, and retreat initial treatment failures. In 2004, a total of 2,658 residents were recruited for 13C urea breath testing. Participants with positive results for infection received a standard 7-day triple therapy (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily), and a 10-day re-treatment (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and levofloxacin 500 mg once daily) if the follow-up tests remained positive. Both H. pylori status and side-effects were assessed 6 weeks after treatment. Among 886 valid reporters, eradication rates with initial therapy were 86.9% (95% confidence interval [CI]: 84.7-89.1%) and 88.7% (95%CI: 86.5-90.9%) by intention-to-treat and per protocol analysis, respectively. Re-treatment eradicated infection in 91.4% (95%CI: 86-96.8%) of 105 non-responders. Adequate compliance was achieved in 798 (90.1%) of 886 subjects receiving the initial treatment and in all 105 re-treated subjects. Mild side effects occurred in 24% of subjects. Overall intention-to-treat and per protocol eradication rates were 97.7% (95%CI: 96.7-98.7%) and 98.8% (95%CI: 98.5-99.3%), respectively, which were only affected by poor compliance (odds ratio [OR], 3.3; 95%CI, 1.99–5.48; P<0.0001). The results first confirmed that clarithromycin-based initial therapy and levofloxacin-based re-treatment is efficacious on a population basis. This approach is safe, well-tolerated, and achieves high eradication rates. Second, a comprehensive plan using drugs in which the resistance rate is low in a population combined with the strategy of test, treat, retest, and retreat of needed can result in virtual eradication of H. pylori from a population. This provides a model for planning country or region wide eradication programs. Part II Though both primary prevention and secondary prevention strategies can reduce the mortality rate of non-cardiac gastric cancer, little is known about their long-term relative cost and benefit. The second part of thesis was to assess the relative cost and effectiveness, optimal initial age and inter-screening interval in a high-risk area regarding primary and secondary preventive strategy. The base-case estimates, including parameters of natural history of gastric cancer, efficacy of intervention and relevant cost, were derived from two empirical data on two interventions targeting at a high-risk population in two periods, 1995-1999 and 2004-2005. Cost and effectiveness was compared between chemoprevention with 13C urea breath testing followed by H pylori eradication and surveillance strategy for high-risk group based on serum pepsinogen (PG) measurements and confirmed by endoscopy. One-way and probabilistic sensitivity analyses were performed to assess the influences of uncertainty of certain parameters. Our main outcome measure was the cost per life-year gained with 3% annual discounted rate. The result showed that the incremental cost-effectiveness ratio (ICER) for one-shot chemoprevention at age 30 y versus no screening was US $17,044 per life-year gained. Eradication of H pylori at later age or with a periodic scheme yielded a less favorable result. Annual high-risk screening at age of 50 y versus no screening resulted in an ICER of US $29,741 per life-year gained. ICERs do not substantially vary with surveillance at various initial ages or with different inter-screening intervals. The chemoprevention was more cost-effective than high-risk surveillance, either at ceiling ratios of US $15,762 or up to US $50,000. The results of cost-effectiveness are most sensitive to the infection rate of H pylori and proportion of early gastric cancer in all detectable cases. In conclusion, we found that early H pylori eradication once in lifetime seems cost-effective than surveillance strategy for high-risk group. However, the choice of population-based preventive strategy is still subject to risk of infection and the detectability of early gastric cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T06:07:17Z (GMT). No. of bitstreams: 1 ntu-95-P93846005-1.pdf: 1110308 bytes, checksum: 715dcf4138a382ae1319dd3407d30162 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 中文摘要..................................................9
英文摘要.................................................13 第一章. 胃癌之現況.......................................16 1.1 胃癌之流行病學..................................16 1.1.1 抗氧化物攝取之影響...............................17 1.1.2 抗生素使用之影響: 幽門桿菌除菌治療...............17 1.1.3 飲食習慣改變之影響...............................18 1.2 馬祖地區胃癌發生之現況..........................19 1.3 幽門螺旋桿菌與胃癌之相關性......................19 1.4 胃癌之癌症發展模式..............................20 1.5 幽門螺旋桿菌、宿主及環境因子之交互作用..........21 1.6 參考文獻........................................23 第二章. 胃癌之防治及文獻回顧.............................28 2.1 胃癌之初段預防...................................28 2.2 以電腦模擬胃癌初段預防之成本效果分析.............31 2.3 胃癌之次段預防...................................34 2.3.1 胃癌之次段預防: 上消化道X光攝影..................34 2.3.2 胃癌之次段預防: 胃蛋白脢原之測量.................35 2.4 比較胃癌之初段預防及次段預防.....................36 2.5 參考文獻.........................................37 第三章. 以幽門桿菌除菌治療為基礎之胃癌初段預防: 檢驗、治療、再檢驗、再治療之效果評估.................................48 3.1 引言............................................48 3.1.1 研究背景........................................48 3.1.2 研究假說........................................49 3.2 方法............................................50 3.2.1 研究族群........................................50 3.2.2 幽門螺旋桿菌之診斷..............................51 3.2.3 治療處方........................................51 3.2.4 統計分析........................................52 3.3 研究結果........................................53 3.3.1 研究族群之基本資料..............................53 3.3.2 幽門螺旋桿菌之除菌治療..........................53 3.3.3 藥物之不良反應..................................54 3.4 討論............................................55 3.4.1 研究之主要發現..................................55 3.4.2 幽門螺旋桿菌第一線藥物治療......................55 3.4.3 幽門螺旋桿菌第二線藥物治療......................56 3.4.4 研究之限制…....................................58 3.5 研究結論........................................59 3.6 參考文獻........................................60 第四章. 胃癌防治計畫之成本效果分析: 比較胃癌之初段預防及次 段預防...................................................69 4.1 引言.............................................69 4.1.1 研究背景.........................................69 4.1.2 研究假說.........................................70 4.2 方法.............................................71 4.2.1 目標族群.........................................71 4.2.2 胃癌篩檢計畫之設計...............................71 4.2.3 電腦模式之設計...................................72 4.2.4 量化胃癌之自然病史...............................73 4.2.5 篩檢策略之模式架構...............................75 4.2.5.1 無篩檢介入之自然病史.............................75 4.2.5.2 以幽門螺旋桿菌除菌治療為手段之初段預防...........75 4.2.5.3 以血清學法為基礎之次段預防.......................76 4.2.6 電腦模式之驗證...................................78 4.2.7 成本效果之分析...................................78 4.2.7.1 確定性之敏感度分析...............................78 4.2.7.2 機率性之敏感度分析...............................78 4.3 研究結果.........................................80 4.3.1 電腦模式之驗證...................................80 4.3.2 基礎值之分析.....................................80 4.3.3 敏感度分析.......................................81 4.3.4 最佳篩檢起始年齡之探討...........................82 4.3.5 最佳篩檢間隔之探討...............................82 4.3.6 可接受度曲線之分析...............................83 4.4 討論.............................................85 4.4.1 研究之主要發現...................................85 4.4.2 胃癌模型之外推性.................................85 4.4.3 胃癌初段預防之最佳處方...........................86 4.4.4 胃癌初段預防與次段預防之比較.....................86 4.4.5 胃癌初段預防之可能缺陷...........................88 4.4.6 本研究之優勢及侷限...............................89 4.5 研究結論.........................................90 4.6 參考文獻........................................91 論文英文版..............................................120 Part I. A Community-based Study of Helicobacter pylori Therapy Using the Strategy of Test, Treat, Retest, and Retreat Initial Treatment Failures................................................121 Part II. Cost-Effectiveness Analysis between Primary and Secondary Preventive Strategies for Gastric Cancer..................................................135 表格 表格2-1. 胃癌與幽門桿菌之相關性: 綜合分析................43 表格2-2. 以幽門桿菌除菌治療為手段之胃癌初段防治..........44 表格2-3. 幽門桿菌除菌治療: 組織學變化為替代終點..........45 表格2-4. 幽門桿菌除菌之初段防治: 電腦模擬成本效果分析....46 表格2-5. 測量胃蛋白脢原診斷胃癌之效果....................47 表格3-1. 參與胃癌初段預防計畫民眾之基本資料..............65 表格3-2. 以開羅里黴素為基礎之三合一藥物治療及可樂必妥為基礎第二線治療之治療效果...........................66 表格3-3. 幽門桿菌除菌治療為手段之胃癌初段防治: 文獻上之治療處方及成效....................................67 表格4-1. 模擬胃癌自然病史之基礎值及敏感度分析之範圍......97 表格4-2. 最佳估計值之下胃癌防治方式增量成本效果比.......100 表格4-3. 單方向之敏感度分析.............................101 附錄表格4-1.以哥利亞胃癌模型為基礎估算馬可夫鏈轉移機率..102 圖說 圖說1-1 台灣好發癌症之發生率趨勢........................25 圖說1-2. 馬祖、台灣及大陸之相對位置.......................26 圖說1-3. 胃癌之癌症發展模式: 哥利亞之模型架構............27 圖說3-1. 參與胃癌初段預防計畫馬祖一般民眾篩檢流程........68 圖說4-1. 參與胃癌次段預防計畫馬祖一般民眾篩檢流程.......105 圖說4-2. 成本效果平面分析: 各種篩檢起始年齡之比較.......106 圖說4-3. 成本效果平面分析: 各種篩檢間隔之比較...........108 圖說4-4. 成本效果可接受度曲線分析.......................110 附錄圖說4-1. 電腦模擬哥利亞胃癌自然病史.................111 附錄圖說4-2. 電腦模擬幽門桿菌除菌治療之胃癌初段預防.....116 附錄圖說4-3. 電腦模擬次段預防介入胃癌自然病史...........120 | |
dc.language.iso | zh-TW | |
dc.title | 以幽門桿菌除菌治療為基礎之胃癌初段預防及其成本效果分析 | zh_TW |
dc.title | Primary Prevention for Gastric Cancer with Helicobacter pylori Eradication and the Cost-Effectiveness Analysis | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 林肇堂(Jaw-Town Lin) | |
dc.contributor.oralexamcommittee | 戴政(John Jen. Tai),張淑惠(Shu-Hui, Chang),楊銘欽(Ming-Chin Yang) | |
dc.subject.keyword | 胃癌,幽門桿菌,疾病自然史,成本效果分析,敏感度分析, | zh_TW |
dc.subject.keyword | gastric cancer,Helicobacter pylori,natural history,cost-effectiveness analysis,sensitivity analysis, | en |
dc.relation.page | 156 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-06-12 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 1.08 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。